A Phase III Clinical Study to Evaluate the Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Healthy Infants
Latest Information Update: 03 Oct 2024
Price :
$35 *
At a glance
- Drugs Pneumococcal 13-valent vaccine conjugate Sinovac Biotech (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sinovac Biotech
- 03 Oct 2024 New trial record